We are monitoring the impact of COVID-19 on APAC Autoimmune Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1108
Share on
Share on

Asia Pacific Autoimmune Monoclonal Antibodies Market Research Report – Segmented By Source, Application, End User & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) – Industry Size, Share, Trends, Growth & Forecasts (2021 to 2026)

Pulished: April, 2021
ID: 1108
Pages: 145

APAC Autoimmune Monoclonal Antibodies Market Size (2021 to 2026)

The size of the Autoimmune Monoclonal Antibodies Market in the Asia Pacific is expected to reach USD 2712.95 million by 2026 from USD 1939.73 million in 2021, growing at a CAGR of 6.94% during the forecast period 2021 to 2026. 

An increase in the prevalence of autoimmune disorders in the region and strategic collaboration and licensing partnerships between the company's safeties enhances the growth of the APAC autoimmune monoclonal antibodies market. Autoimmune disorders are conditions in which the body's immune system attacks healthy tissue. Autoantibodies are produced in autoimmune diseases, attacking the body's healthy cells. Autoimmune monoclonal antibodies are immunotherapy drugs that prevent healthy cells in the body from being damaged. In addition, the potential of mAbs in basic research and clinical applications has been enhanced because of advancements in mAb development methods. Therefore, the market is predicted to grow healthy throughout the forecast period, owing to a wide range of uses and efficacy in illness treatment.

Chronic and rare diseases are a key revenue growth driver in the autoimmune monoclonal antibody industry. For example, patients with cancer require long-term medicine and frequent delivery of mAb as directed throughout therapy. Along with disease prevalence, industry players' development efforts to create new products will bolster market growth. The market for autoimmune monoclonal antibodies is driven by the rising number of patients with severe arthritis and multiple sclerosis. In addition, the market for autoimmune monoclonal antibodies has grown due to a rise in the family history of immunological disease.

One disadvantage of mAb-based medications is that they are highly selective and have restricted targets. This is because they interact with cells rather than penetrate them. This has impacted the market to some extent. Another disadvantage of employing mAbs is that they must be injected, unlike small molecule medications. However, stringent FDA guidelines for approving new treatments may hamper the APAC autoimmune monoclonal antibodies market.

This research report on the APAC Autoimmune Monoclonal Antibodies Market has been segmented and sub-segmented into the following categories

By Source:

  • Murine
  • Chimeric
  • Humanized
  • Human

By Application:

  • Systemic Lupus Erythematosus
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Transplant Rejection/Graft Versus Host Disease

By End-User: 

  • Hospitals/Clinics
  • Research Institutes
  • Diagnostic Laboratories

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Due to a growth in the frequency of arthritis and related conditions and the availability of generic medications, Asia-Pacific is predicted to account for the most significant market share in the autoimmune monoclonal antibodies market in the future years. Asia-Pacific offers good opportunities for key players in the monoclonal antibodies market due to a growth in the number of initiatives and higher government investment for overall R&D of monoclonal antibody therapy and a rise in the number of products approvals. Furthermore, ongoing advancements in monoclonal antibodies, the availability of sophisticated healthcare systems, and significant growth in demand for advanced healthcare facilities are projected to boost the market. Furthermore, leading manufacturers' increased attention on increasing their geographical presence in growing Asia-Pacific countries to acquire high market share is predicted to fuel the region's monoclonal antibody market expansion. Cancer is a group of chronic diseases marked by uncontrolled cell proliferation. As the number of cancer patients rises, demand for monoclonal antibodies is predicted to rise, propelling the industry forward. According to GLOBOCAN, Asia Pacific saw a 45.8 percent increase in new breast cancer cases in 2018. According to the World Health Organization (WHO), approximately 18.1 million cancer cases and 9.6 million deaths worldwide in 2018.

KEY MARKET PLAYERS:

Companies playing a prominent role in the APAC Autoimmune Monoclonal Antibodies market include GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc.(U.S.), and UCB Company (Belgium).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Source                    

                                5.1.1 Murine     

                                5.1.2 Chimeric  

                                5.1.3 Humanized             

                                5.1.4 Human     

                5.2 By Application                           

                                5.2.1 Systemic Lupus Erythematosus      

                                5.2.2 Rheumatoid Arthritis          

                                5.2.3 Multiple Sclerosis 

                                5.2.4 Transplant Rejection/Graft Versus Host Disease     

                                5.2.5 Others      

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

6. Geographical Analysis                                              

                6.1 Asia-Pacific                 

                                6.1.1 Introduction           

                                6.1.2 China         

                                6.1.3 India          

                                6.1.4 Japan        

                                6.1.5 South Korea           

                                6.1.6 Australia  

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Monoclonal Antibodies Development                 

                                7.5.1 Targeted Therapies             

                7.6 Promising Monoclonal Antibodies in Pipeline                              

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies                   

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 GlaxoSmithKline plc (U.K.)                   

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 AstraZeneca plc (U.K.)                           

                9.6 Innovent Biologics, Inc. (China)                          

                9.4 Bristol-Myers Squibb (U.S.)                 

                9.5 Johnson & Johnson (U.S.)                    

                9.6 Innovent Biologics, Inc. (China)                          

                9.7 Takeda Pharmaceutical Company Ltd. (Japan)                             

                9.8 Amgen Inc. (U.S.)                     

                9.9 Biogen Inc.(U.S.)                      

                9.10 UCB Company (Belgium)                    

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures    

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Autoimmune Monoclonal Antibodies Market By Region, From 2021 to 2026 (USD Million)
  2. Asia-Pacific Autoimmune Monoclonal Antibodies Market By Source, From 2021 to 2026 (USD Million)
  3. Asia-Pacific Murine Monoclonal Antibodies Market By Region, From 2021 to 2026 (USD Million)
  4. Asia-Pacific Chimeric Monoclonal Antibodies Market By Region, From 2021 to 2026 (USD Million)
  5. Asia-Pacific Humanized Monoclonal Antibodies Market By Region, From 2021 to 2026 (USD Million)
  6. Asia-Pacific Human Monoclonal Antibodies Market By Region, From 2021 to 2026 (USD Million)
  7. Asia-Pacific Autoimmune Monoclonal Antibodies Market By Appliation, From 2021 to 2026 (USD Million)
  8. Asia-Pacific Systemic Lupus Erythematosus Market By Region, From 2021 to 2026 (USD Million)
  9. Asia-Pacific Rheumatoid Arthritis Market By Region, From 2021 to 2026 (USD Million)
  10. Asia-Pacific Multiple Sclerosis Market By Region, From 2021 to 2026 (USD Million)
  11. Asia-Pacific Transplant Rejection/Graft Versus Host Disease Market By Region, From 2021 to 2026 (USD Million)
  12. Asia-Pacific Other Applications Market By Region, From 2021 to 2026 (USD Million)
  13. Asia-Pacific Autoimmune Monoclonal Antibodies Market By End User, From 2021 to 2026 (USD Million)
  14. Asia-Pacific Hospitals/Clinics Market By Region, From 2021 to 2026 (USD Million)
  15. Asia-Pacific Research Institute Market By Region, From 2021 to 2026 (USD Million)
  16. Asia-Pacific Diagnostic Laboratories Market By Region, From 2021 to 2026 (USD Million)
  17. China Autoimmune Monoclonal Antibodies Market By Source, From 2021 to 2026 (USD Million)
  18. China Autoimmune Monoclonal Antibodies Market By Application, From 2021 to 2026 (USD Million)
  19. China Autoimmune Monoclonal Antibodies Market By End User, From 2021 to 2026 (USD Million)
  20. India Autoimmune Monoclonal Antibodies Market By Source, From 2021 to 2026 (USD Million)
  21. India Autoimmune Monoclonal Antibodies Market By Application, From 2021 to 2026 (USD Million)
  22. India Autoimmune Monoclonal Antibodies Market By End User, From 2021 to 2026 (USD Million)
  23. Japan Autoimmune Monoclonal Antibodies Market By Source, From 2021 to 2026 (USD Million)
  24. Japan Autoimmune Monoclonal Antibodies Market By Application, From 2021 to 2026 (USD Million)
  25. Japan Autoimmune Monoclonal Antibodies Market By End User, From 2021 to 2026 (USD Million)
  26. South Korea Autoimmune Monoclonal Antibodies Market By Source, From 2021 to 2026 (USD Million)
  27. South Korea Autoimmune Monoclonal Antibodies Market By Application, From 2021 to 2026 (USD Million)
  28. South Korea Autoimmune Monoclonal Antibodies Market By End User, From 2021 to 2026 (USD Million)
  29. Australia Autoimmune Monoclonal Antibodies Market By Source, From 2021 to 2026 (USD Million)
  30. Australia Autoimmune Monoclonal Antibodies Market By Application, From 2021 to 2026 (USD Million)
  31. Australia Autoimmune Monoclonal Antibodies Market By End User, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample